



AHCCCS Pharmacy & Therapeutics Committee Public Testimony Form

1 message

donotreply@magellanhealth.com <donotreply@magellanhealth.com> Thu, Apr 27, 2023 at 11:43 AM
Reply-To: "AHCCCSPharmacyDept@azahcccs.gov" <AHCCCSPharmacyDept@azahcccs.gov>,
"terryj@magellanhealth.com" <terryj@magellanhealth.com>
To: AHCCCSPharmacyDept@azahcccs.gov, terryj@magellanhealth.com, NURSING@sanpedrohealth.net

Name: JAMES REED
Company or Organization: SAN PEDRO HEALTH
Business Address: 4151 LA LINDA WAY, STE 102
Business City: SIERRA VISTA
Business State: AZ
Preferred Email Address: NURSING@SANPEDROHEALTH.NET
Phone: 5205159610
Representation: Unchecked
Affiliation: Checked

Please check the box of the statement that best applies.:
I do not have a current or recent (within the last 24 months) financial arrangement or affiliation with any organization that may have a direct interest in the business before the AHCCCS P&T Committee.

Summary of Testimony: We are requesting that AHCCCS increase the availability to and improve approval of Lybalvi for FDA approved diagnoses. Please remove onerous restrictions placed on Lybalvi, a potentially life saving medication for many suffering from Bipolar Disorder and Schizophrenia. Currently its use is requiring TRIAL AND FAILURE of 5 agents before being approved. AHCCCS patients in particular are at higher risk of having negative outcomes psychiatrically. Allowing the same restrictions as other medications in its class decreases that possibility/probability.

Drug/Product: Lybalvi
Therapeutic Drug Class: Atypical Antipsychotics
Testimony Format: Written

Confidentiality Notice This electronic message transmission contains information belonging to Magellan Health, its subsidiaries or affiliates, that is solely for the recipient named above and which may be confidential or privileged. MAGELLAN HEALTH, its subsidiaries or affiliates, EXPRESSLY PRESERVES AND ASSERTS ALL PRIVILEGES AND IMMUNITIES APPLICABLE TO THIS TRANSMISSION. If you are not the intended recipient, be aware that any disclosure, copying, distribution or use of this communication is STRICTLY PROHIBITED. If you have received this electronic transmission in error, please notify us at . Thank you.